Beleodaq

Active Ingredient(s): Belinostat
FDA Approved: * July 3, 2014
Pharm Company: * SPECTRUM PHARMS
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Beleodaq Overview

Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.[2] It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.[3] In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer.[4&a...

Read more Beleodaq Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Belinostat

Recent Beleodaq Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Belinostat
  • Injection: 500mg
  • Powder: 500mg/vial
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Beleodaq: (1 result)

Sorted by National Drug Code
  • 68152-108 Beleodaq 500 mg/10ml Intravenous Injection, Powder, Lyophilized, for Solution by Spectrum Pharmaceuticals, Inc.

Other drugs which contain Belinostat or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 26 April 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA